<DOC>
	<DOCNO>NCT02156804</DOCNO>
	<brief_summary>The purpose study determine rate frequency high-grade ( CTCAE v4.0 Grade 3 high ) , treatment-related , select adverse event subject histologically confirm stage III ( unresectable ) stage IV melanoma progression post prior treatment contain anti-Cytotoxic T Lymphocyte Antigen ( CTLA-4 ) monoclonal antibody , treat Nivolumab ( BMS-936558 ) dose 3 mg/kg every two week .</brief_summary>
	<brief_title>A Single-Arm , Open-Label , Multicenter Clinical Trial With Nivolumab ( BMS-936558 ) Subjects With Histologically Confirmed Stage III ( Unresectable ) Stage IV Melanoma Progressing Post Prior Treatment Containing Anti-CTLA4 Monoclonal Antibody ( CheckMate 172 )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects histologically confirm malignant melanoma Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) : PS 0 1 PS 2 Previously treat unresectable stage III stage IV melanoma per American Joint Committee Cancer 2010 Guidelines regardless BRAF mutation status Subjects must experience evaluable Response Evaluation Criteria In Solid Tumors ( RECIST 1.1 ) define disease progression Prior treatment chemotherapy , interferon ( adjuvant setting ) , Interleukin ( IL2 ) , BRAF/MEK inhibitor subject know BRAF mutation , Mitogenactivated extracellular signal regulate protein kinase ( MEK ) inhibitor Neuroblastoma Ras Viral ( vras ) oncogene homolog ( NRAS ) mutation , cKIT inhibitor subject know cKIT mutation allow Patients CNS metastases eligible : CNS metastasis treat , patient asymptomatic neurologically return baseline previously untreated CNS metastases asymptomatic leptomeningeal metastasis , treat asymptomatic neurologically return baseline life expectancy &gt; 3 month Patients known history Grades 34 immunerelated adverse reaction during/after antiCTLA4 therapy toxicity resolve least Grade 1 Subjects untreated , active Central Nervous System ( CNS ) metastases excluded</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>